These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 24871704

  • 1. The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis.
    Fu J, Chen Y.
    Psychopharmacology (Berl); 2015 Jan; 232(1):7-16. PubMed ID: 24871704
    [Abstract] [Full Text] [Related]

  • 2. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder.
    Pae CU, Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Serretti A.
    J Psychiatry Neurosci; 2015 May; 40(3):174-86. PubMed ID: 25350320
    [Abstract] [Full Text] [Related]

  • 3. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older.
    Nomikos GG, Tomori D, Zhong W, Affinito J, Palo W.
    CNS Spectr; 2017 Aug; 22(4):348-362. PubMed ID: 27869048
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder.
    Boulenger JP, Loft H, Olsen CK.
    Int Clin Psychopharmacol; 2014 May; 29(3):138-49. PubMed ID: 24257717
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms.
    Baldwin DS, Florea I, Jacobsen PL, Zhong W, Nomikos GG.
    J Affect Disord; 2016 Dec; 206():140-150. PubMed ID: 27474960
    [Abstract] [Full Text] [Related]

  • 8. [Vortioxetine in the treatment of major depression].
    de Bartolomeis A, Fagiolini A, Maina G.
    Riv Psichiatr; 2016 Dec; 51(6):215-230. PubMed ID: 27996982
    [Abstract] [Full Text] [Related]

  • 9. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Li G, Wang X, Ma D.
    Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
    Baune BT, Sluth LB, Olsen CK.
    J Affect Disord; 2018 Mar 15; 229():421-428. PubMed ID: 29331703
    [Abstract] [Full Text] [Related]

  • 12. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.
    Mahableshwarkar AR, Jacobsen PL, Chen Y, Serenko M, Trivedi MH.
    Psychopharmacology (Berl); 2015 Jun 15; 232(12):2061-70. PubMed ID: 25575488
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.
    Baldwin DS, Chrones L, Florea I, Nielsen R, Nomikos GG, Palo W, Reines E.
    J Psychopharmacol; 2016 Mar 15; 30(3):242-52. PubMed ID: 26864543
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME.
    Int J Neuropsychopharmacol; 2013 Mar 15; 16(2):313-21. PubMed ID: 22963932
    [Abstract] [Full Text] [Related]

  • 18. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults.
    Thase ME, Mahableshwarkar AR, Dragheim M, Loft H, Vieta E.
    Eur Neuropsychopharmacol; 2016 Jun 15; 26(6):979-93. PubMed ID: 27139079
    [Abstract] [Full Text] [Related]

  • 19. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
    Alam MY, Jacobsen PL, Chen Y, Serenko M, Mahableshwarkar AR.
    Int Clin Psychopharmacol; 2014 Jan 15; 29(1):36-44. PubMed ID: 24169027
    [Abstract] [Full Text] [Related]

  • 20. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
    Jacobsen PL, Harper L, Chrones L, Chan S, Mahableshwarkar AR.
    Int Clin Psychopharmacol; 2015 Sep 15; 30(5):255-64. PubMed ID: 26020712
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.